Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Antonia, S.
Villegas, A.
Daniel, D.
Vicente, D.
Murakami, S.
Hui, R.
Kurata, T.
Chiappori, A.
Lee, K. H.
De Wit, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
NSCLC, durvalumab, PACIFIC